Allele-specific silencing therapy for Dynamin 2-related diseases
US10947540B2 · kind B2 · utility
3Cited by
0References
13Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Nov 19, 2017 |
| Grant date | Mar 16, 2021 |
| Priority date | — |
| Expiry date | Nov 19, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Y306/05005
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to an allele specific siRNA able to silence the expression of only one allele of a heterozygous DNM2 gene, for treating diseases caused by heterozygous mutation and/or overexpression of Dynamin 2.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.